Cover
Cover - USD ($) | 12 Months Ended | ||
Oct. 31, 2020 | Mar. 22, 2021 | Apr. 30, 2020 | |
Cover [Abstract] | |||
Entity Registrant Name | HUAIZHONG HEALTH GROUP, INC. | ||
Entity Central Index Key | 0001593204 | ||
Document Type | 10-K | ||
Amendment Flag | false | ||
Entity Voluntary Filers | No | ||
Current Fiscal Year End Date | --10-31 | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Small Business | true | ||
Entity Shell Company | true | ||
Entity Emerging Growth Company | false | ||
Entity Current Reporting Status | Yes | ||
Document Period End Date | Oct. 31, 2020 | ||
Entity Filer Category | Non-accelerated Filer | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2020 | ||
Entity Common Stock Shares Outstanding | 31,518,466 | ||
Entity Public Float | $ 415,000 | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity File Number | 000-55369 | ||
Entity Incorporation State Country Code | NV | ||
Entity Tax Identification Number | 90-1020141 | ||
Entity Address Address Line 1 | Tianan Technology Park | ||
Entity Address Address Line 2 | 13/F Headquarters Center Building 16 | ||
Entity Address Address Line 3 | 555 Panyu North Ave | ||
Entity Address City Or Town | Guangzhou City | ||
Entity Address Country | CN | ||
Entity Address Postal Zip Code | 00000 | ||
City Area Code | 86 | ||
Local Phone Number | 2982 9356 | ||
Entity Interactive Data Current | Yes |
BALANCE SHEETS
BALANCE SHEETS - USD ($) | Oct. 31, 2020 | Oct. 31, 2019 |
Current Assets | ||
Cash | $ 0 | $ 0 |
Total Current Assets | 0 | 0 |
Total Assets | 0 | 0 |
Current Liabilities | ||
Accounts payable and accrued liabilities | 10,913 | 11,141 |
Due to related party | 8,559 | 0 |
Convertible notes payable | 0 | 9,956 |
Total Current Liabilities | 19,472 | 21,097 |
Total Liabilities | 19,472 | 21,097 |
Stockholders' Deficit | ||
Common stock: 750,000,000 shares authorized; $0.001 par value 31,518,466 and 517,853 shares issued and outstanding at October 31, 2020 and 2019, respectively | 31,518 | 518 |
Additional paid in capital | 257,587 | 250,482 |
Accumulated deficit | (308,577) | (272,097) |
Total Stockholders' Deficit | (19,472) | (21,097) |
Total Liabilities and Stockholders' Deficit | $ 0 | $ 0 |
BALANCE SHEETS (Parenthetical)
BALANCE SHEETS (Parenthetical) - $ / shares | Oct. 31, 2020 | Oct. 31, 2019 |
STOCKHOLDERS' EQUITY (DEFECIENCY) | ||
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock shares authorized | 750,000,000 | 750,000,000 |
Common stock shares issued | 31,518,466 | 517,853 |
Common stock shares outstanding | 31,518,466 | 517,853 |
STATEMENTS OF OPERATIONS (Unaud
STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 12 Months Ended | |
Oct. 31, 2020 | Oct. 31, 2019 | |
STATEMENTS OF OPERATIONS (Unaudited) | ||
Revenue | $ 0 | $ 0 |
Operating Expenses: | ||
Professional fees | 35,101 | 26,097 |
General and administrative | 900 | 100,000 |
Total operating expenses | 36,001 | 126,097 |
Operating Loss | (36,001) | (126,097) |
Other income (expense) | ||
Interest expense | (479) | 0 |
Total other expense | (479) | 0 |
Net loss before taxes | (36,480) | (126,097) |
Income tax benefit | 0 | 0 |
Net Loss | $ (36,480) | $ (126,097) |
Net loss per common share, basic and diluted | $ 0 | $ (0.41) |
Basic and diluted weighted average common shares outstanding | 10,455,090 | 308,946 |
STATEMENTS OF CHANGES IN SHAREH
STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIENCY) (UNAUDITED) - USD ($) | Total | Common Stock | Additional Paid-In Capital | Accumulated Deficit |
Balance, shares at Oct. 31, 2018 | 255,353 | |||
Balance, amount at Oct. 31, 2018 | $ 0 | $ 255 | $ 145,745 | $ (146,000) |
Common stock issued for compensation- related party, shares | 250,000 | |||
Common stock issued for compensation- related party, amount | 100,000 | $ 250 | 99,750 | 0 |
Common stock issued for conversion of convertible note- related party, shares | 12,500 | |||
Common stock issued for conversion of convertible note- related party, amount | 5,000 | $ 13 | 4,988 | 0 |
Net loss | (126,097) | $ 0 | 0 | (126,097) |
Forgiveness of due to related party | 0 | |||
Balance, shares at Oct. 31, 2019 | 517,853 | |||
Balance, amount at Oct. 31, 2019 | (21,097) | $ 518 | 250,482 | (272,097) |
Common stock issued for conversion of convertible note- related party, shares | 31,000,000 | |||
Common stock issued for conversion of convertible note- related party, amount | 31,000 | $ 31,000 | 0 | 0 |
Net loss | (36,480) | $ 0 | 0 | (36,480) |
Common stock issued for rounding on the reverse split, shares | 613 | |||
Common stock issued for rounding on the reverse split, amount | 0 | $ 0 | 0 | 0 |
Forgiveness of due to related party | 2,405 | 0 | 2,405 | 0 |
Forgiveness of convertible note payable - related party | 4,700 | $ 0 | 4,700 | 0 |
Balance, shares at Oct. 31, 2020 | 31,518,466 | |||
Balance, amount at Oct. 31, 2020 | $ (19,472) | $ 31,518 | $ 257,587 | $ (308,577) |
STATEMENTS OF CASH FLOWS (Unaud
STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 12 Months Ended | |
Oct. 31, 2020 | Oct. 31, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss | $ (36,480) | $ (126,097) |
Changes in current assets and liabilities: | ||
Related party advances funding operations | 36,229 | 14,956 |
Stock based compensation - related party | 0 | 100,000 |
Accounts payable and accrued liabilities | 251 | 11,141 |
Net cash used in operating activities | 0 | 0 |
Net change in cash for the year | 0 | 0 |
Cash at beginning of year | 0 | 0 |
Cash at end of end | 0 | 0 |
SUPPLEMENTAL CASH FLOW INFORMATION: | ||
Cash paid for income taxes | 0 | 0 |
Cash paid for interest | 0 | 0 |
NON-CASH INVESTING AND FINANCING ACTIVITIES | ||
Issuance of common stock as equity compensation - former related party | 0 | 100,000 |
Issuance of common stock for conversion of convertible note- related party | 31,000 | 5,000 |
Forgiveness of due to related party | 2,405 | 0 |
Forgiveness of convertible note payable and accrued interest - related party | $ 4,700 | $ 0 |
Organization and Going Concern
Organization and Going Concern | 12 Months Ended |
Oct. 31, 2020 | |
Organization and Going Concern | |
Note 1 - Organization and Going Concern | Note 1 - Organization and Going Concern Adaiah Distribution, Inc. (the “Company”), is a for profit corporation established under the corporation laws in the State of Nevada, United States of America on September 12, 2013. Effective December 15, 2020, the company changed its operation name to Huaizhong Health Group, Inc. (the Company). Our principal office is located at Tianan Technology Park, 13/F Headquarters Center Building 16, 555 Panyu North Ave, Panyu District, Guangzhou City, China. The Company’s fiscal year end is October 31. The Company was in the development phase of its custom pillow distribution business. During the third fiscal quarter ending July 31, 2018 the Company had ceased its operations of its Pillow manufacturing and sales. The Company is not currently engaged in any business operations. It is however seeking to identify, locate and if warranted acquire new commercial opportunities. Change of Control On August 12, 2020, Yosef Yafe ( the “Seller”) and Yuantong Wang (the “Buyer”) entered into a stock purchase agreement, pursuant to which the Seller agreed to sell and the Buyer agreed to purchase an aggregate of 31,000,000 shares of common stock of the Company from the Seller. As of the date referenced in this action, the Company had 31,518,466 shares of common stock outstanding. The securities purchased represented 98.4% of the outstanding shares of common stock and 98.4% of the voting power of the Company. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of October 31, 2020, the Company has suffered recurring losses from operations, has an accumulated deficit of $308,577 and has not earned any revenues. The Company intends to fund operations through equity financing arrangements and related party advances, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending October 31, 2021. The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty |
Significant Accounting Policies
Significant Accounting Policies and Recent Accounting Pronouncements | 12 Months Ended |
Oct. 31, 2020 | |
Significant Accounting Policies and Recent Accounting Pronouncements | |
Note 2 - Significant Accounting Policies and Recent Accounting Pronouncements | Note 2: Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation The Financial Statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Financial Statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (“GAAP”) of the United States. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments Cash and Cash Equivalents Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company had no cash at October 31, 2020 and 2019, respectively. Fair Value of Measurements ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2020 and 2019. The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. Basic and Diluted Loss Per Common Share The Company computes earnings (loss) per share in accordance with ASC 260-10-45 “Earnings per Share”, which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic earnings (loss) per share is computed by dividing net earnings (loss) available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. For the years ended October 31, 2019, convertible notes which were convertible were dilutive instruments and are not included in the calculation of diluted loss per share as their effect would be antidilutive. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized Recent Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements. Reclassification Certain accounts from prior periods have been reclassified to conform to the current period presentation. |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Oct. 31, 2020 | |
Stockholders' Equity | |
Note 3 - Stockholders' Equity | Note 3 – Stockholders’ Equity The Company has 750,000,000 shares of common stock authorized with a par value of $0.001 per share. On September 5, 2019, the Company issued 250,000 common shares of the company to the former CEO pursuant to the equity compensation agreement signed August 10, 2019. On September 5, 2019, the Company issued 12,500 common shares of the Company to the former CEO upon conversion of $5,000 of the convertible note signed on August 10, 2019. On April 28, 2020, the majority shareholders of the Company voted to effect a reverse split of 400-to-1 on its common shares. The authorized amount of 750,000,000 is to be unchanged and hence the par value of the Company of $0.001 is also to remain unchanged. On June 5, 2020, FINRA approved the reverse split and it became effective on that date. All historical share balances and share price related data in this annual report have been adjusted based on the 400-to-1 reverse split ratio. On June 5, 2020, concurrent with the reverse split the Company issued new additional 613 shares to certain shareholders as part of rounding differences. On July 7, 2020, the Company issued 31,000,000 common shares of the Company to the former CEO upon conversion of $31,000 of the convertible note at the conversion rate of $0.001 per common shares. As of October 31, 2020, and 2019, there were 31,518,466 and 517,853 shares of common stock issued and outstanding, respectively. |
Income Taxes
Income Taxes | 12 Months Ended |
Oct. 31, 2020 | |
Income Taxes | |
Note 4 - Income Taxes | Note 4 - Income Taxes The Company provides for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. The components of the Company’s deferred tax asset and reconciliation of income taxes computed at the statutory rate of 21% to the income tax amount recorded as of October 31, 2020 and 2019 are as follows: October 31, October 31, 2020 2019 Net Operating Loss $ (36,480 ) $ (126,097 ) Effective tax rate 21 % 21 % Income Tax expense (7,661 ) (26,480 ) Less: valuation allowance 7,661 26,480 Income Tax Expense $ - $ - Net deferred tax assets consist of the following components as of October 31, 2020 and 2019: October 31, October 31, 2020 2019 Net Operating Loss carryforward $ 64,801 $ 57,140 Valuation allowance (64,801 ) (57,140 ) Net deferred tax asset $ - $ - At October 31, 2020, the Company had $380,577 of net operating losses ( “NOLs”), which begin to expire beginning in 2037. NOLs generated in tax years prior to July 31, 2018, can be carryforward for twenty years, whereas NOLs generated after July 31, 2018 can be carryforward indefinitely The NOL carry forwards are subject to certain limitations due to the change in control of the Company pursuant to Internal Revenue Code Section 382. The Company experienced a change in control for tax purposes in August 2020 (see Note 1). Due to change of control, the Company will not be able to carryover approximately $294,765 of NOL generated before August 12, 2020 to offset future income. |
Convertible Note
Convertible Note | 12 Months Ended |
Oct. 31, 2020 | |
Convertible Note | |
Note 5 - Convertible Note | Note 5 – Convertible Note - Related Party On August 10, 2019 the Company signed a convertible note for funds being paid in cash for settlement of vendors’ invoices on behalf of the Company by the former CEO, as of that date for a twelve month period following that date which can be converted by the CEO at any time into restricted common shares of the Company at a conversion rate of $0.001 per share. The note bears interest of 4% per annum. The note is currently in default. For the years ended October 31, 2020 and 2019, the Company recorded interest expense of $479 and $0, respectively. On August 12, 2020, in connection with change of control and stock purchase agreement (Note 1), the former CEO forgave the convertible note of $4,221 and accrued interest of $479. As of October 31, 2020, and 2019, the Company was obligated for this convertible note with balance of $0 and $9,956, and accrued interest of $0 and $0, respectively. |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Oct. 31, 2020 | |
Related Party Transactions | |
Note 6- Related Party Transactions | Note 6 – Related Party Transactions In June 2019, the Company entered into a compensation agreement with the former CEO whereby the CEO would receive a onetime compensation of $50,000 for being elected as the CEO and sole director of the Company and $10,000 per month through October 31, 2019 for his continued services through then. According to the agreement, the compensation was to be paid in the form of restricted common stock of the Company at a value of its par which is $0.001 per share. The Company signed a resolution in the third fiscal quarter of the fiscal year ending October 31, 2019 issuing 250,000 shares of restricted common stock of the Company to the former CEO valued at $100,000 which compromises the $50,000 onetime compensation and five months of compensation of an aggregate of $50,000, pursuant to the compensation agreement. During the year ended October 31, 2020, the amount due to the former CEO of $2,405, for payment of vendors’ invoices were forgiven. During the years ended October 31, 2020 and 2019, the former CEO paid vendors’ invoice of $25,265 and $14,956, respectively. During the years ended October 31, 2020, and 2019, $31,000 was converted into 31,000,000 restricted common shares of the Company and $5,000 was converted into 12,500 restricted common shares of the Company, respectively. During the year ended October 31, 2020, the Company’s sole officer and director advanced to the Company an amount of $8,559 by paying for expenses on behalf of the Company. As of October 31, 2020, and 2019, the Company was obligated to the officer, for an unsecured, non-interest-bearing demand loan with a balance of $8,559 and $0, respectively. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Oct. 31, 2020 | |
Subsequent Events | |
Note 7 - Subsequent Events | Note 7 – Subsequent Events The Company has evaluated subsequent events from October 31, 2020, through the date these financial statements were issued and determined the following events require disclosure: On December 14, 2020, the Company filed Articles of Conversion/Exchange/Merger, with the state of Nevada, to change its name to “Huaizhong Health Group, Inc.” (the "Name Change"). The Name Change became effective as of December 15, 2020. The Company’s CEO has advanced an additional $12,188 for payment of operating expenses. |
Significant Accounting Polici_2
Significant Accounting Policies and Recent Accounting Pronouncements (Policies) | 12 Months Ended |
Oct. 31, 2020 | |
Significant Accounting Policies and Recent Accounting Pronouncements | |
Basis of Presentation | The Financial Statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Financial Statements have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles (“GAAP”) of the United States. |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments |
Cash and Cash Equivalents | Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company had no cash at October 31, 2020 and 2019, respectively. |
Fair Value of Measurements | ASC 825, “Disclosures about Fair Value of Financial Instruments”, requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of October 31, 2020 and 2019. The respective carrying values of certain on-balance-sheet financial instruments approximate their fair values. These financial instruments include accrued liabilities and notes payable. Fair values were assumed to approximate carrying values for these financial instruments since they are short term in nature and their carrying amounts approximate fair value. |
Basic and Diluted Loss Per Common Share | The Company computes earnings (loss) per share in accordance with ASC 260-10-45 “Earnings per Share”, which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic earnings (loss) per share is computed by dividing net earnings (loss) available to common stockholders by the weighted average number of outstanding common shares during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company. For the years ended October 31, 2019, convertible notes which were convertible were dilutive instruments and are not included in the calculation of diluted loss per share as their effect would be antidilutive. |
Income Taxes | Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized |
Recent Accounting Pronouncements | The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial statements. |
Reclassification | Certain accounts from prior periods have been reclassified to conform to the current period presentation. |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Oct. 31, 2020 | |
Income Taxes | |
Schedule of deferred tax asset and reconciliation of income taxes | October 31, October 31, 2020 2019 Net Operating Loss $ (36,480 ) $ (126,097 ) Effective tax rate 21 % 21 % Income Tax expense (7,661 ) (26,480 ) Less: valuation allowance 7,661 26,480 Income Tax Expense $ - $ - |
Schedule of Net deferred tax assets | October 31, October 31, 2020 2019 Net Operating Loss carryforward $ 64,801 $ 57,140 Valuation allowance (64,801 ) (57,140 ) Net deferred tax asset $ - $ - |
Organization and Going Concern
Organization and Going Concern (Details Narrative) - USD ($) | Aug. 12, 2020 | Oct. 31, 2020 | Oct. 31, 2019 |
Percentage of Voting power | 98.40% | ||
Percentage of securities purchased common stock shares outstanding | 98.40% | ||
Accumulated deficit | $ (308,577) | $ (272,097) | |
Common stock shares outstanding | 31,518,466 | 517,853 | |
Yuantong Wang [Member] | |||
Common stock shares outstanding | 31,518,466 | ||
Purchase of aggregate Common Stock | 31,000,000 |
Stockholders' Equity (Details N
Stockholders' Equity (Details Narrative) - USD ($) | Aug. 10, 2019 | Oct. 31, 2020 | Apr. 28, 2020 | Oct. 31, 2019 | Sep. 05, 2019 |
Common stock, shares authorized | 750,000,000 | 750,000,000 | 750,000,000 | ||
Common stock, par value | $ 0.001 | ||||
Common stock shares outstanding | 31,518,466 | 517,853 | |||
Common stock, shares issued | 31,518,466 | 517,853 | |||
Stockholders equity reverse stock split | 400-to-1 | ||||
Debt Conversion, Converted Rate | 4.00% | ||||
Convertible note | $ 0 | $ 9,956 | |||
CEO [Member] | |||||
Common stock, shares issued | 250,000 | ||||
Debt conversion, converted instrument, shares issued | 12,500 | ||||
Debt conversion, converted instrument, amount | $ 31,000 | ||||
June 5, 2020 [Member] | |||||
Common stock shares issued, as part of rounding differences | 613 | ||||
June 07, 2020 [Member] | Convertible Notes Payable [Member] | CEO [Member] | |||||
Debt conversion, converted instrument, shares issued | 31,000,000 | ||||
Debt conversion, converted instrument, amount | $ 31,000 | ||||
Debt Conversion, Converted Rate | 0.001% | ||||
September 05, 2019 [Member] | |||||
Common stock, shares issued | 12,500 | ||||
Convertible note | $ 5,000 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 12 Months Ended | |
Oct. 31, 2020 | Oct. 31, 2019 | |
Income Taxes | ||
Net Operating Loss | $ (36,480) | $ (126,097) |
Effective tax rate | 21.00% | 21.00% |
Income Tax expense | $ (7,661) | $ (26,480) |
Less: valuation allowance | 7,661 | 26,480 |
Income Tax Expense | $ 0 | $ 0 |
Income Taxes (Details 1)
Income Taxes (Details 1) - USD ($) | 12 Months Ended | |
Oct. 31, 2020 | Oct. 31, 2019 | |
Income Taxes | ||
Net Operating Loss carryforward | $ 64,801 | $ 57,140 |
Valuation allowance | (64,801) | (57,140) |
Net deferred tax asset | $ 0 | $ 0 |
Income Taxes (Details Narrative
Income Taxes (Details Narrative) - USD ($) | 12 Months Ended | ||
Oct. 31, 2020 | Oct. 31, 2019 | Aug. 12, 2020 | |
Net operating losses | $ (36,001) | $ (126,097) | |
Net operating losses carryforward | 64,801 | $ 57,140 | |
Deferred Tax Assets [Member] | |||
Net operating losses | $ (380,577) | ||
Net operating losses carryforward | $ (294,765) |
Convertible Note (Details Narra
Convertible Note (Details Narrative) - USD ($) | Aug. 12, 2020 | Aug. 10, 2019 | Oct. 31, 2020 | Oct. 31, 2019 |
Convertible Note | ||||
Interest expense | $ 479 | $ 479 | $ 0 | |
Obligated to convertible note | $ 4,221 | 0 | 9,956 | |
Interest rate | 4.00% | |||
Debt Conversion, Converted Rate | $ 0.001 | |||
Accrued interest | $ 0 | $ 0 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | 9 Months Ended | 12 Months Ended | |
Jul. 31, 2020 | Oct. 31, 2020 | Oct. 31, 2019 | |
sole officer [Member] | |||
Expenses paid on the behalf of company | $ 8,559 | ||
Non-interest-bearing demand loan | 8,559 | $ 0 | |
CEO [Member] | |||
Restricted common stock, amount | $ 31,000 | ||
Restricted common stock issued | 31,000,000 | ||
Debt conversion, converted instrument, amount | $ 5,000 | ||
Due to related party debt | 2,405 | ||
Vendors payment paid by related party | $ 25,265 | 14,956 | |
Debt conversion, converted instrument, shares issued | 12,500 | ||
Convertible Notes Payable [Member] | Chief Executive Officer [Member] | |||
Compensation paid | 50,000 | ||
Compensation paid per month | $ 10,000 | ||
Restricted common stock, par value | $ 0.001 | ||
Restricted common stock, amount | $ 100,000 | ||
Restricted common stock issued | 250,000 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) | 12 Months Ended |
Oct. 31, 2020USD ($) | |
CEO [Member] | |
Payment of operating expenses | $ 12,188 |